Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

McMaster University

$24,000.00

Elucidating the mechanism of action of Mirexus Biotechnologies Inc.'s immunomodulatory phytoglyogen (IM-PhG) in increasing virus vector production

EF 2018-19

Résumé
Millions of dollars are spent on the research, development and commercialization of new therapies to treat*virus infections, vaccines, virus-based gene therapy vectors and, more recently, oncolytic viruses that target and*kill cancer. While significant gains have been made in the development of these therapeutic tools, several key*roadblocks remain, including the need to develop more generic antiviral therapies that target a wide range of*known and new emerging viruses and the need to optimize virus-based vaccine and vector production to make*these products commercially viable from both a cost and manufacturing perspective.*Mirexus Biotechnologies is a biomedical company actively developing novel nano-medicines for a variety of*clinical indications. Their technology platform is based on renewable, non-toxic glycogen, or sugar, from corn.*Phytoglycogen (PhG) can be easily altered by chemists. Indeed, one modification was shown to change the*immune stimulating properties of PhG (IM-PhG). More specifically, IM-PhG can decrease the primary immune*response in cells. As a result, a higher yield of viruses can be obtained from the cells, overcoming one of the*current roadblocks to making virus-based therapies.*The goal of this proposal is to understand the mechanism of how IM-PhG alters the environment within the*cell, allowing for a higher level of virus production. To ensure safety and to optimize virus production, it is*critical to understand how IM-PhG is functioning. These studies will also allow ""smart engineering"" by*chemists of more potent versions of PhG.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
523780-2018
Name nom
Mossman, Karen
Department département
Pathology and Molecular Medicine
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
24000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5111
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Signal transduction
Research subject fr
Transduction de signal
Partie
1
Nb partie
1
Application title
Elucidating the mechanism of action of Mirexus Biotechnologies Inc.'s immunomodulatory phytoglyogen (IM-PhG) in increasing virus vector production
Keyword
NSERC
Application summary
Millions of dollars are spent on the research, development and commercialization of new therapies to treat*virus infections, vaccines, virus-based gene therapy vectors and, more recently, oncolytic viruses that target and*kill cancer. While significant gains have been made in the development of these therapeutic tools, several key*roadblocks remain, including the need to develop more generic antiviral therapies that target a wide range of*known and new emerging viruses and the need to optimize virus-based vaccine and vector production to make*these products commercially viable from both a cost and manufacturing perspective.*Mirexus Biotechnologies is a biomedical company actively developing novel nano-medicines for a variety of*clinical indications. Their technology platform is based on renewable, non-toxic glycogen, or sugar, from corn.*Phytoglycogen (PhG) can be easily altered by chemists. Indeed, one modification was shown to change the*immune stimulating properties of PhG (IM-PhG). More specifically, IM-PhG can decrease the primary immune*response in cells. As a result, a higher yield of viruses can be obtained from the cells, overcoming one of the*current roadblocks to making virus-based therapies.*The goal of this proposal is to understand the mechanism of how IM-PhG alters the environment within the*cell, allowing for a higher level of virus production. To ensure safety and to optimize virus production, it is*critical to understand how IM-PhG is functioning. These studies will also allow ""smart engineering"" by*chemists of more potent versions of PhG.